Comparing two chemotherapies for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy drug combinations (FOLFOX-6 and CAPOX) to see which works better and has fewer side effects for people with colorectal cancer that has spread. It may help you and your doctor choose the best treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 70 years old
- You have colorectal cancer that has spread to other parts of the body (metastatic)
- You had surgery to remove the tumor and are now receiving chemotherapy
- You do not have another cancer besides colorectal cancer
- You have no history of a brain or nerve disorder (like stroke, Parkinson's, or neuropathy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations for people with advanced colorectal cancer that has grown after first treatment. It tests whether a newer drug (fruquintinib) combined with standard chemotherapy works as well as the current standard (bevacizumab) combined with chemotherapy.
This trial compares two standard chemotherapy combinations for people whose colorectal cancer has spread and cannot be removed with surgery. Depending on certain genetic markers, participants also receive either bevacizumab or cetuximab to help the treatment work better.
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This trial compares two different chemotherapy combinations given before radiation or surgery for high-risk locally advanced rectal cancer. One arm is more intense, and the other is standard. The goal is to see which works better at shrinking the tumor and possibly avoiding surgery.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
Hear when a new Metastatic Colorectal Carcinoma (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.